@article{2ca6c3b128c14fb494c73e03a4046003,
title = "Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations",
abstract = "The components of the Switch/Sucrose non-fermentable (SWI/SNF) complex are mutated in approximately 20% of human cancers. The A/T-rich interacting domain 1A (ARID1A) subunit has one of the highest mutation rates. Most notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas (OCCCs). We reported that inhibition of enhancer of zeste homology 2 (EZH2) is synthetically lethal in ARID1A-mutated OCCC.",
author = "Bitler, {Benjamin G.} and Aird, {Katherine M.} and Rugang Zhang",
note = "Funding Information: This work was supported by grants from the US National Institutes of Health/National Cancer Institute (R01CA160331 and R01CA163377 to R. Z. and Cancer Center Support grant CA010815 to the Wistar Institute), a US Department of Defense Ovarian Cancer Academy award (OC093420 to R.Z.), and an Ovarian Cancer Research Fund Program project (to R.Z.). R.Z. is an Ovarian Cancer Research Fund Liz Tilbe- ris Scholar. B.G.B. is supported by an American Cancer Society postdoctoral fellowship (PF-13–058–01-TBE). K.M.A. is supported by a training grant from the US National Institutes of Health/National Cancer Institute (T32CA9171–35). Publisher Copyright: {\textcopyright} 2016, {\textcopyright} 2016 Taylor & Francis Group, LLC.",
year = "2016",
month = jan,
day = "2",
doi = "10.1080/23723556.2015.1032476",
language = "English (US)",
volume = "3",
journal = "Molecular and Cellular Oncology",
issn = "2372-3556",
publisher = "Taylor and Francis Ltd.",
number = "1",
}